- For Part 2 Only: Platinum-resistant ovarian cancer, or Triple Negative Breast Cancer with measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in at least 1 lesion that in the opinion of the Investigator is appropriate to treat with nab-paclitaxel.